Helen Ha

发表

Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnover.

N. Neamati, Helen Ha, 2014, Molecular pharmaceutics.

Role of the CXCL 8-CXCR 1 / 2 Axis in Cancer and Inflammatory Diseases

N. Neamati, B. Debnath, Helen Ha, 2017 .

Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models

Henry Ho, Bikash Debnath, Helen Ha, 2015, J. Chem. Inf. Model..

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

N. Neamati, B. Debnath, Helen Ha, 2017, Theranostics.

Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction

Maxim N. Artyomov, M. Artyomov, Yu-Sung Hsu, 2023, bioRxiv.

Antigen glycosylation regulates efficacy of CAR T cells targeting CD19

M. Weitzman, R. Fluhrer, Yu-Sung Hsu, 2022, Nature Communications.

Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort

B. Henderson, C. Haiman, L. Kolonel, 2009, BMC Cancer.

Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity.

N. Neamati, Z. Debyser, F. Christ, 2012, Journal of medicinal chemistry.

A novel phenylcyclohex‐1‐enecarbothioamide derivative inhibits CXCL8‐mediated chemotaxis through selective regulation of CXCR2‐mediated signalling

N. Neamati, P. Beringer, Timothy J. Bensman, 2014, British journal of pharmacology.

DMH4, a VEGFR2 inhibitor, effectively suppresses growth and invasion of lung cancer cells

J. Hao, Xiao Ding, L. Zhong, 2018 .

Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction.

Maxim N. Artyomov, M. Artyomov, Yu-Sung Hsu, 2023, Blood.

Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9,10-dione derivatives.

N. Neamati, Nattaya Ngamrojanavanich, N. Muangsin, 2013, Bioorganic & medicinal chemistry letters.